Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Virus or component thereof
Reexamination Certificate
2008-04-04
2011-12-27
Chen, Stacy B. (Department: 1648)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Virus or component thereof
C435S235100, C435S243000
Reexamination Certificate
active
08084039
ABSTRACT:
Embodiments herein relate to compositions of and methods for live viruses. In certain embodiments, a live, attenuated virus composition includes, but is not limited to, one or more live, attenuated viruses and compositions to reduce inactivation and/or degradation of the live, attenuated virus. In other embodiments, the live, attenuated virus composition may be a vaccine composition. In yet other compositions, a live, attenuated virus composition may include at least one carbohydrate, at least one protein and at least one high molecular weight surfactants for reducing inactivation and/or degradation of the live, attenuated virus.
REFERENCES:
patent: 2005/0255121 (2005-11-01), Campbell et al.
patent: 2005/0276785 (2005-12-01), Groetzbach et al.
patent: 2003086433 (2003-10-01), None
patent: 2003087327 (2003-10-01), None
International Search Report and Written Opinion for PCT/US2008/059472, mailed Dec. 16, 2008.
Bhardwaj et al., “Controlled-release delivery system for the alpha-MSH analog melanotan-I using poloxamer 407,” J Pharm Sci 1996, 85(9):915-19.
Burke et al., “Formulation, stability, and delivery of live attenuated vaccines for human use,” Crit Rev in Therapeutic Drug Carrier Systems 1999, 16(1):1-83.
Coeshott et al., “Pluronic F127-based systemic vaccine delivery systems,” Vaccine 2004, 22:2396-2405.
Desai et al., “Evaluation of Pluronic F127-based sustained-release ocular delivery systems for pilocarpine using the albino rabbit eye model,” J Pharm Sci 1998, 87(10):1190-1195.
Kabanov et al., “Pluronic block copolymers for overcoming drug resistance in cancer,” Adv Drug Delivery Rev 2002, 54:759-779.
Katakam et al., “Use of polaxamer polymers to stabilize recombinant human growth hormone against various processing stresses,” Pharmaceutical Dev Technol 1997, 2(2):143-149.
Miyazaki et al., “Percutaneous absorption of indomethacin from Pluronic F127 gels in rats,” J Pharm Pharmacol 1995, 47:455-7.
Newman et al., “Design and development of adjuvant-active nonionic block copolymers,” J Pharm Sci 1998, 87 (11):1357-62.
Strappe et al., “Delivery of a lentiviral vector in a Pluronic F127 gel to cells of the central nervous system,” Eur J Pharm Biopharm 2005, 61:126-33.
Westerink et al., “ProJuvant (Pluronic F127/chitosan) enhances the immune response to intranasally administered tetanus toxoid,” Vaccine 2002, 20:711-23.
Chinese Office Action with English Translation, Application No. 200880018784.3, Oct. 27, 2010.
Danish Patent and Trademark Office Singapore Written Opinion, Application No. 200906668-9, Nov. 30, 2010.
New Zealand Examination Report, Application No. 580978, Oct. 14, 2010.
Extended European Search Report, for EP Application No. EP 2 144 99, dated Oct. 6, 2011.
Osorio Jorge E.
Stinchcomb Dan T.
Wiggan O'Neil
Chen Stacy B.
Faegre & Benson LLP
Inviragen, Inc.
LandOfFree
Methods and compositions for live attenuated viruses does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods and compositions for live attenuated viruses, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods and compositions for live attenuated viruses will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4267480